Cytochrome P450 and steatosis

Current Drug Metabolism

Volumn 10, Issue 7, 2009, Pages 692-699

  Gómez Lechón, María José ^a,b   Jover, Ramiro ^a,b,c   Donato, María Teresa ^a,b,c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 4A; DRUG METABOLIZING ENZYME; HALOPERIDOL; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHENOBARBITAL; PROPOFOL; TRIACYLGLYCEROL;

AEROBIC METABOLISM; APOPTOSIS; DOWN REGULATION; DRUG HYDROXYLATION; DRUG SAFETY; FATTY ACID TRANSPORT; FATTY LIVER; GENE ACTIVITY; GENE EXPRESSION; GENE TARGETING; HUMAN; LIPID PEROXIDATION; LIPID STORAGE; LIVER CELL; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION REGULATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; FATTY LIVER; GENE EXPRESSION REGULATION; HUMANS; PHARMACEUTICAL PREPARATIONS; TRANSCRIPTION, GENETIC;

EID: 72949085334     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009789895543     Document Type: Review

References (85)

1. Yu, A.S.; Keeffe, E.B. Nonalcoholic fatty liver disease. Rev. Gastroenterol. Disord., 2002, 2(1), 11-19.
2. Duvnjak, M.; Lerotić, I.; Barsić, N.; Tomasić, V.; Virović Jukic, L.; Velagić, V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J. Gastroenterol., 2007, 13 (34), 4539-4550.
3. Koebnick, C.; Getahun, D.; Reynolds, K.; Coleman, K.J.; Porter, A.H.; Lawrence, J.M.; Punyanitya, M.; Quinn, V.P.; Jacobsen, S.J. Trends in nonalcoholic fatty liver disease-related hospitalizations in US children, adolescents, and young adults. J. Pediatr. Gastroenterol. Nutr., 2009, 48(5), 597-603.
4. Cheung, O.; Sanyal, A.J. Recent advances in nonalcoholic fatty liver disease. Curr. Opin. Gastroenterol., 2009, 25 (3), 230-237.
5. Farrell, G.C.; Larter, C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology, 2006, 43(2 Suppl 1), S99-S112.
6. Cheymol, G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin. Pharmacokinet., 2000, 39 (3), 215-231.
7. Villeneuve, J.P.; Pichette, V. Cytochrome P450 and liver diseases. Curr. Drug. Metab., 2004, 5(3), 273-282.
8. Weltman, M.D.; Farrell, G.C.; Liddle, C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology, 1996, 111(6), 1645-1653.
9. Leclercq, I.; Horsmans, Y. ; Desager, J.P. ; Delzenne, N.; Geubel, A.P. Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J. Hepatol., 1998, 28(3), 410-416.
10. Su, G.M.; Sefton, R.M.; Murray, M. Down-regulation of rat hepatic microsomal cytochromes P-450 in microvesicular steatosis induced by orotic acid. J. Pharmacol. Exp. Ther., 1999, 291(3), 953-959.
11. Donato, M.T.; Lahoz, A,; Jimenez, N.; Perez, G.; Serralta, A.; Mir, J.; Castell, J.V.; Gomez-Lechon, M.J. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab. Dispos., 2006, 34 (9), 1556-1562.
12. Cave, M.; Deaciuc, I.; Mendez, C.; Song, Z.; Joshi-Barve, S.; Barve, S.; McClain, C. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J. Nutr. Biochem., 2007, 18 (3), 184-195.
13. den Boer, M.; Voshol, P.J.; Kuipers, F.; Havekes, L.M.; Romijn, J.A. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler. Thromb. Vasc. Biol., 2004, 24 (4), 644-649.
14. Choi, S.S.; Diehl, A.M. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr. Opin. Lipidol., 2008, 19 (3), 295-300.
15. Grieco, A.; Forgione, A.; Miele, L.; Vero, V.; Greco, A.V.; Gasbarrini, A.; Gasbarrini, G. Fatty liver and drugs. Eur. Rev. Med. Pharmacol. Sci., 2005, 9(5), 261-263.
16. Postic, C.; Girard, J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab., 2008, 34(6 Pt 2),643-648.
17. Tamura, S.; Shimomura, I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J. Clin. Invest., 2005, 115(5), 1139-1142.
18. George, J.; Liddle, C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol. Pharm., 2008, 5(1), 49-59.
19. Browning, J.D.; Horton, J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest., 2004 ,114 (2), 147-152.
20. Donnelly, K.L.; Smith, C.I.; Schwarzenberg, S.J.; Jessurun, J.; Boldt, M.D.; Parks, E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest., 2005, 115 (5), 1343-1351.
21. Araya, J.; Rodrigo, R.; Videla, L.A.; Thielemann, L.; Orellana, M.; Pettinelli, P.; Poniachik, J. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. (Lond)., 2004, 106, 635-643.
22. Shimomura, I.; Shimano, H.; Korn, B.S.; Bashmakov, Y.; Horton, J.D. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J. Biol. Chem., 1998, 273, 35299-35306.
23. Chitturi, S.; Abeygunasekera, S.; Farrell, G.C.; Holmes-Walker, J.; Hui, J.M.; Fung, C.; Karim, R.; Lin, R.; Samarasinghe, D.; Liddle, C.; Weltman, M.; George, J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology, 2002, 35, 373-379.
24. Sanyal, A.J.; Campbell-Sargent, C.; Mirshahi, F.; Rizzo, W.B.; Contos, M.J.; Sterling, R.K.; Luketic, V.A.; Shiffman, M.L.; Clore, J.N. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 2001, 120(5), 1183-1192.
25. Leclercq, I.A.; Farrell, G.C.; Field, J.; Bell, D.R.; Gonzalez, F.J.; Robertson, G.R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J. Clin. Invest., 2000, 105(8), 1067-1075.
26. Feldstein, A.E.; Canbay, A.; Angulo, P.; Taniai, M.; Burgart, L.J.; Lindor, K.D.; Gores, G.J. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology, 2003, 125(2),437-443.
27. Day, C.P.; James, O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology., 1998 , 114 (4), 842-845.
28. Gentile, C.L.; Pagliassotti, M.J. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J. Nutr. Biochem., 2008, 19(9), 567-76.
29. Tessari, P.; Cracina, A.; Cosma, A.; Tiengo, A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr. Metab. Cardivasc. Dis., 2009, 19, 291-302.
30. Malhi, H.; Gores, G.J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin. Liver Dis., 2008, 28(4), 360-369.
31. Lieber, C.S. Cytochrome P-4502E1: its physiological and pathological role. Physiol. Rev., 1997, 77(2), 517-544.
32. Restrepo, J.G.; Garcia-Martín, E.; Martínez, C.; Agúndez, J.A. Polymorphic drug metabolism in anaesthesia. Curr. Drug Metab., 2009, 10(3), 236-246.
33. Raucy, J.L.; Lasker, J.M.; Kraner, J.C.; Salazar, D.E.; Liebre, C.S.; Corcovan, G.B. Induction of cytochrome P450IIE1 in the obese overfed rat. Mol. Pharmacol., 1991, 39(3), 275-280.
34. Emery, M.G.; Fisher, J.M.; Chien, J.Y.; Kharasch, E.D.; Dellinger, E.P.; Kowdley, K.V.; Thummel, K.E. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology, 2003, 38(2), 428-435.
35. Gonzalez, F.J. The 2006 Bernard B. Brodie award lecture. Cyp2e1. Drug Metab. Dispos., 2007, 35(1), 1-8.
36. Murray, M. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clin. Pharmacokinet., 1992, 23(2), 132-146.
37. Murray, M.; Cantrill, E.; Mehta, I.; Farrell, G.C. Impaired expression of microsomal cytochrome P450 2C11 in choline-deficient rat liver during the development of cirrhosis. J. Pharmacol. Exp. Ther., 1992, 261(1), 373-380.
38. Paintaud, G.; Bechtel, Y.; Brientini, M.P.; Miguet, J.P.; Bechtel, P.R. Effects of liver diseases on drug metabolism. Therapie, 1996, 51(4),384-389.
39. Kraul, H.; Truckenbrodt, J.; Huster, A.; Töpfer, R.; Hoffmann, A. Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity. Eur. J. Clin. Pharmacol., 1991, 41(5), 475-480.
40. Weltman, M.D.; Farrell, G.C.; Hall, P.; Ingelman-Sundberg, M.; Liddle, C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology, 1998, 27(1), 128-133.
41. Kolwankar, D.; Vuppalanchi, R.; Ethell, B.; Jones, D.R.; Wrighton, S.A.; Hall, S.D.; Chalasani, N. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin. Gastroenterol. Hepatol., 2007, 5(3),388-393.
42. Yamazaki, H.; Iketaki, H.; Shibata, A.; Nakajima, M.; Yokoi, T. Activities of cytochrome p450 enzymes in liver and kidney microsomes from systemic carnitine deficiency mice with a gene mutation of carnitine/organic cation transporter. Drug Metab. Pharmacokinet., 2002, 17(1), 47-53.
43. Lieber, C.S.; Leo, M.A.; Mak, K.M.; Xu, Y.; Cao, Q.; Ren, C.; Ponomarenko, A.; DeCarli, L.M. Model of nonalcoholic steatohepatitis. Am. J. Clin. Nutr., 2004, 79, 502-509.
44. Sugatani, J.; Wada, T.; Osabe, M.; Yamakawa, K.; Yoshinari, K.; Miwa, M. Dietary insulin alleviates hepatic steatosis and xenobiotics-induced liver injury in rats fed a high-fat and high-sucrose diet: association with the suppression of hepatic cytochrome P450 and hepatocyte nuclear factor 4alpha expression. Drug Metab. Dispos., 2006, 34(10),1677-1687.
45. Zhang, W.V.; Ramzan, I.; Murray, M. Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J. Pharmacol. Exp. Ther., 2007, 322(2), 770-777.
46. Osabe, M.; Sugatani, J.; Fukuyama, T.; Ikushiro, S.; Ikari, A.; Miwa, M. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab. Dispos., 2008, 36(2),294-302.
47. Ito, Y.; Abril, E.R.; Bethea, N.W.; McCuskey, M.K.; McCuskey, R.S. Dietary steatotic liver attenuates acetaminophen hepatotoxicity in mice. Microcirculation, 2006, 13(1), 19-27.
48. Hanagama, M.; Inoue, H.; Kamiya, M.; Shinone, K.; Nata, M. Gene expression on liver toxicity induced by administration of haloperidol in rats with severe fatty liver. Leg. Med. (Tokyo), 2008, 10(4), 177-184.
49. Kam, P.C.; Cardone, D. Propofol infusion syndrome. Anaesthesia, 2007, 62(7), 690-701.
50. Videla, L.A.; Rodrigo, R.; Orellana, M.; Fernandez, V.; Tapia, G.; Quiñones, L.; Varela, N.; Contreras, J.; Lazarte, R.; Csendes, A.; Rojas, J.; Malvenda, F.; Burdiles, P.; Diaz, J.C.; Smok, G.; Thielemann, L.; Poniachik, J. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin. Sci. (Lond)., 2004, 106(3), 261-268.
51. Donato, M.T.; Jimenez, N.; Serralta, A.; Mir, J.; Castell, J.V.; Gomez-Lechon, M.J. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol. In Vitro, 2007, 21 (2), 271-276.
52. Gómez-Lechón, M.J.; Donato, M.T.; Martínez-Romero, A.; Jiménez, N.; Castell, J.V.; O'Connor, J.E. A human hepatocellular in vitro model to investigate steatosis. Chem. Biol. Interact., 2007, 165(2), 106-116.
53. Benson, G.D.; Koff, R.S.; Tolman, K.G. The therapeutic use of acetaminophen in patients with liver disease. Am. J. Ther., 2005, 12 (2), 133-141.
54. Laine, J.E.; Auriola, S.; Pasanen, M.; Juvonen, R.O. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica, 2009, 39(1), 11-21.
55. Donthamsetty, S.; Bhave, V.S.; Mitra, M.S. ; Latendresse, J.R. ; Mehendale, H.M. Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate. Toxicol. Appl. Pharmacol., 2008, 230 (3), 327-337.
56. Jump, D.B.; Botolin, D.; Wang, Y.; Xu, J.; Christian, B.; Demeure, O. Fatty acid regulation of hepatic gene transcription. J. Nutr., 2005, 135(11), 2503-2506.
57. Anderson, N.; Borlak, J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev., 2008, 60 (3), 311-357.
58. Gaemers, I.C.; Groen, A.K. New insights in the pathogenesis of non-alcoholic fatty liver disease. Curr. Opin. Lipidol., 2006, 17(3), 268-273.
59. Kalaany, N.Y.; Mangelsdorf, D.J. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol., 2006, 68, 159-191.
60. Grimaldi, P.A. Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives. Cell. Mol. Life Sci., 2007, 64(19-20), 2459-2464.
61. Kallwitz, E.R.; McLachlan, A.; Cotler, S.J. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol., 2008, 14(1), 22-28.
62. Barbier, O.; Fontaine, C.; Fruchart, J.C.; Staels, B. Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes. Trends Endocrinol. Metab., 2004, 15 (7), 324-330.
63. Chen, W.; Chen, G.; Head, D.L.; Mangelsdorf, D.J.; Russell, D.W. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab., 2007, 5(1): 73-79.
64. Ou, J.; Tu, H.; Shan, B.; Luk, A.; DeBose-Boyd, R.A.; Bashmakov, Y.; Goldstein, J.L.; Brown, M.S. Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc. Natl. Acad. Sci. USA, 2001, 98(11), 6027-6032.
65. Beaudet, M.J.; Desrochers, M.; Lachaud, A.A.; Anderson, A. The CYP2B2 phenobarbital response unit contains binding sites for hepatocyte nuclear factor 4, PBX-PREP1, the thyroid hormone receptor beta and the liver X receptor. Biochem. J., 2005, 388 (Pt 2), 407-418.
66. Gnerre, C.; Schuster, G.U.; Roth, A.; Handschin, C.; Johansson, L.; Looser, R.; Parini, P.; Podvinec, M.; Robertsson, K.; Gustafsson, J.A.; Meyer, U.A. LXR deficiency and cholesterol feeding affect the expression and phenobarbital-mediated induction of cytochromes P450 in mouse liver. J. Lipid Res., 2005, 46(8), 1633-1642.
67. Gnerre, C.; Blattler, S.; Kaufmann, M.R.; Looser, R.; Meyer, U.A. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics, 2004, 14(10), 635-645.
68. Zhao, A.; Yu, J.; Lew, J.L.; Huang, L.; Wright, S.D.; Cui, J. Poly-unsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. DNA Cell Biol., 2004, 23(8), 519-526.
69. Goodwin, B.; Jones, S.A.; Price, R.R.; Watson, M.A.; McKee, D.D.; Moore, L.B.; Galardi, C.; Wilson, J.G.; Lewis, M.C.; Roth, M.E.; Maloney, P.R.; Willson, T.M.; Kliewer, S.A. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell, 2000, 6(3), 517-526.
70. Huang, J.; Iqbal, J.; Saha, P.K.; Liu, J.; Chan, L.; Hussain, M.M.; Moore, D.D.; Wang, L. Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology, 2007, 46(1), 147-157.
71. Ourlin, J.C.; Lasserre, F.; Pineau, T.; Fabre, J.M.; Sa-Cunha, A.; Maurel, P.; Vilarem, M.J.; Pascussi, J.M. The small heterodimer partner interacts with the pregnane X receptor and represses its transcriptional activity. Mol. Endocrinol., 2003, 17(9), 1693-1703.
72. Bae, Y.; Kemper, J.K.; Kemper, B. Repression of CAR-mediated transactivation of CYP2B genes by the orphan nuclear receptor, short heterodimer partner (SHP). DNA Cell Biol., 2004, 23 (2), 81-91.
73. Li, T.; Chiang, J.Y. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug. Metab. Dispos., 2006, 34(5), 756-764.
74. Konno, Y.; Negishi, M.; Kodama, S. The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. Drug Metab. Pharmacokinet., 2008, 23(1), 8-13.
75. Moreau, A.; Vilarem, M.J.; Maurel, P.; Pascussi, J.M. Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol. Pharm., 2008, 5(1), 35-41.
76. Finn, R.D.; Henderson, C.J.; Scott, C.L.; Wolf, C.R. Unsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway. Biochem. J., 2009, 417(1), 43-54.
77. Li, C.C.; Lii, C.K.; Liu, K.L.; Yang, J.J.; Chen, H.W. n-6 and n-3 polyunsaturated fatty acids down-regulate cytochrome P-450 2B1 gene expression induced by phenobarbital in primary rat hepatocytes. J. Nutr. Biochem., 2006, 17(10), 707-715.
78. Li, C.C.; Lii, C.K.; Liu, K.L.; Yang, J.J.; Chen, H.W. DHA down-regulates phenobarbital-induced cytochrome P450 2B1 gene expression in rat primary hepatocytes by attenuating CAR translocation. Toxicol. Appl. Pharmacol., 2007, 225(3), 329-336.
79. Watkins, R.E.; Wisely, G.B.; Moore, L.B.; Collins, J.L.; Lambert, M.H.; Williams, S.P.; Willson, T.M.; Kliewer, S.A.; Redinbo, M.R. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science, 2001, 292(5525), 2329-2333.
80. Xue, Y.; Moore, L.B.; Orans, J.; Peng, L.; Bencharit, S.; Kliewer, S.A.; Redinbo, M.R. Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol. Endocrinol., 2007, 21(5), 1028-1038.
81. Shenoy, S.D.; Spencer, T.A.; Mercer-Haines, N.A.; Alipour, M.; Gargano, M.D.; Runge-Morris, M.; Kocarek, T.A. CYP3A induction by liver x receptor ligands in primary cultured rat and mouse hepatocytes is mediated by the pregnane X receptor. Drug Metab. Dispos., 2004, 32(1), 66-71.
82. Duniec-Dmuchowski, Z.; Ellis, E.; Strom, S.C.; Kocarek, T.A. Regulation of CYP3A4 and CYP2B6 expression by liver X receptor agonists. Biochem. Pharmacol., 2007, 74(10), 1535-1540.
83. Dhe-Paganon, S.; Duda, K.; Iwamoto, M.; Chi, Y.I.; Shoelson, S.E. Crystal structure of the HNF4 alpha ligand binding domain in complex with endogenous fatty acid ligand. J. Biol. Chem., 2002, 277(41), 37973-37976.
84. Wisely, G.B.; Miller, A.B,; Davis, R.G.; Thornquest, A.D.Jr.; Johnson, R.; Spitzer, T.; Sefler, A.; Shearer, B.; Moore, J.T.; Willson, T.M.; Williams, S.P. Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure, 2002, 10(9), 1225-1234.
85. Jover, R.; Bort, R.; Gomez-Lechon, M.J.; Castell, J.V. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology, 2001, 33(3), 668-675.